Finepoint Capital LP Spring Works Therapeutics, Inc. Transaction History
Finepoint Capital LP
- $1.18 Billion
- Q4 2024
A detailed history of Finepoint Capital LP transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Finepoint Capital LP holds 748,752 shares of SWTX stock, worth $42.3 Million. This represents 2.29% of its overall portfolio holdings.
Number of Shares
748,752
Previous 650,852
15.04%
Holding current value
$42.3 Million
Previous $20.9 Million
29.73%
% of portfolio
2.29%
Previous 2.17%
Shares
9 transactions
Others Institutions Holding SWTX
# of Institutions
236Shares Held
67.2MCall Options Held
260KPut Options Held
316K-
Vanguard Group Inc Valley Forge, PA7.16MShares$405 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$318 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.46MShares$196 Million5.51% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.27MShares$185 Million0.01% of portfolio
-
State Street Corp Boston, MA3MShares$170 Million0.0% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $3.53B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...